Kimia Biosciences Ltd.
Kimia Biosciences Ltd. Fundamental Analysis
Kimia Biosciences Ltd. (KIMIABL.BO) shows moderate financial fundamentals with a PE ratio of 12.31, profit margin of 7.19%, and ROE of 92.05%. The company generates $1.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze KIMIABL.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakKIMIABL.BO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentKIMIABL.BO trades at attractive valuation levels.
Growth Score
WeakKIMIABL.BO faces weak or negative growth trends.
Financial Health Score
WeakKIMIABL.BO carries high financial risk with limited liquidity.
Profitability Score
WeakKIMIABL.BO struggles to sustain strong margins.
Key Financial Metrics
Is KIMIABL.BO Expensive or Cheap?
P/E Ratio
KIMIABL.BO trades at 12.31 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, KIMIABL.BO's PEG of 1.18 indicates fair valuation.
Price to Book
The market values Kimia Biosciences Ltd. at 9.62 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 3.64 times EBITDA. This is generally considered low.
How Well Does KIMIABL.BO Make Money?
Net Profit Margin
For every $100 in sales, Kimia Biosciences Ltd. keeps $7.19 as profit after all expenses.
Operating Margin
Core operations generate 12.82 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $92.05 in profit for every $100 of shareholder equity.
ROA
Kimia Biosciences Ltd. generates $8.92 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Kimia Biosciences Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Kimia Biosciences Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
KIMIABL.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.31
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.18
vs 25 benchmark
P/B Ratio
Price to book value ratio
9.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.88
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
3.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.91
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.92
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.54
vs 25 benchmark
How KIMIABL.BO Stacks Against Its Sector Peers
| Metric | KIMIABL.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.31 | 27.91 | Better (Cheaper) |
| ROE | 92.05% | 687.00% | Weak |
| Net Margin | 7.19% | -45285.00% (disorted) | Weak |
| Debt/Equity | 3.11 | 0.33 | Weak (High Leverage) |
| Current Ratio | 0.91 | 2795.76 | Weak Liquidity |
| ROA | 8.92% | -13557.00% (disorted) | Weak |
KIMIABL.BO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Kimia Biosciences Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation